| Literature DB >> 22173333 |
Kamal F M Atta1, Omaima O M Farahat, Somaya M Ghobashy, Mohamed G Marei.
Abstract
The formation ofEntities:
Mesh:
Substances:
Year: 2011 PMID: 22173333 PMCID: PMC6264286 DOI: 10.3390/molecules161210387
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of 3-{2-(2,5-diphenylpyrazolo[1,5-c]pyrimidin-7-yl)hydrazono}indolin-2-ones 3.
Figure 1Isomerisation of (E)-3-{2-(2,5-diphenylpyrazolo[1,5-c]pyrimidin-7-yl)hydrazono}indolin-2-ones (E)-3.
Scheme 2Electrophilic substitution reactions of 3-{2-(2,5-diphenylpyrazolo[1,5-c]pyrimidin-7-yl)hydrazono}indolin-2-ones (E or Z)-3.
Scheme 3Annulation of 2,5-diphenylindolo[2,3-e]pyrazolo[1',5':3",4"]pyrimido[2",1"-c][1,2,4]triazines.
Minimum inhibitory concentration (MIC) (µg/mL) of compounds 3–7 and 13–16 against selected bacterial strains.
| Compound No. | Gram-positive | Gram-negative | |||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| MIC (µg/mL) | |||||
| ( | >256 | >256 | >256 | >256 | >256 |
| ( | >256 | >256 | >256 | ||
| ( | >256 | >256 | >256 | >256 | >256 |
| ( | >256 | >256 | >256 | >256 | >256 |
| ( | >256 | >256 | >256 | >256 | |
| ( | >256 | >256 | >256 | >256 | >256 |
| ( | >256 | >256 | >256 | >256 | >256 |
| ( | >256 | >256 | >256 | >256 | |
| ( | >256 | >256 | >256 | >256 | >256 |
| ( | >256 | >256 | >256 | >256 | >256 |
| ( | >256 | >256 | >256 | >256 | >256 |
| ( | >256 | >256 | >256 | >256 | |
| ( | >256 | >256 | >256 | >256 | >256 |
| ( | >256 | >256 | >256 | >256 | >256 |
| ( | >256 | >256 | >256 | >256 | |
| ( | >256 | >256 | >256 | ||
| ( | >256 | >256 | >256 | >256 | |
| ( | >256 | >256 | >256 | >256 | >256 |
| >256 | >256 | >256 | >256 | >256 | |
| >256 | >256 | >256 | >256 | ||
| >256 | >256 | >256 | >256 | >256 | |
| >256 | >256 | >256 | |||
| >256 | >256 | >256 | >256 | >256 | |
| >256 | >256 | >256 | >256 | ||
| >256 | >256 | >256 | >256 | ||
| >256 | >256 | >256 | >256 | >256 | |
| >256 | >256 | >256 | >256 | ||
| >256 | >256 | >256 | >256 | >256 | |